Ovid Therapeutics (OVID) announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N., as Chief Medical Officer. Dr. Kaufmann joins Ovid from Vigil Neuroscience where she served as Chief Medical Officer
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OVID:
- Ovid Therapeutics price target raised to $2 from $1.50 at H.C. Wainwright
- Leerink bullish on Ovid Therapeutics, initiates with an Outperform
- Ovid Therapeutics initiated with an Outperform at Leerink
- Ovid Therapeutics: Promising Pipeline and Strong Financials Justify Buy Rating
- Ovid Therapeutics Reports Q3 2025 Financial Results